View Rule
View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
HHS/SAMHSA | RIN: 0930-AA38 | Publication ID: Spring 2022 |
Title: Treatment of Opioid Use Disorder With Buprenorphine Utilizing Telehealth | |
Abstract:
In the face of an escalating overdose crisis and an increasing need to reach remote and underserved communities, extending the buprenorphine telehealth flexibility is of paramount importance. To permanently continue this flexibility among OTPs after the COVID-19 public health emergency ends, SAMHSA proposes to revise OTP regulations under 42 CFR part 8. |
|
Agency: Department of Health and Human Services(HHS) | Priority: Other Significant |
RIN Status: Previously published in the Unified Agenda | Agenda Stage of Rulemaking: Proposed Rule Stage |
Major: Yes | Unfunded Mandates: No |
CFR Citation: 42 CFR 8.11 (h) | |
Legal Authority: The Controlled Substances Act, as amended by the Ryan Haight Act (21 U.S.C. sec. 802(54)(G)) |
Legal Deadline:
None |
||||||
Timetable:
|
Regulatory Flexibility Analysis Required: No | Government Levels Affected: None |
Small Entities Affected: Businesses | Federalism: No |
Included in the Regulatory Plan: Yes | |
RIN Data Printed in the FR: No | |
Agency Contact: Dr. Neeraj Gandotra Chief Medical Officer Department of Health and Human Services Substance Abuse and Mental Health Services Administration 5600 Fishers Lane, 18E67, Rockville, MD 20857 Phone:202 823-1816 Email: neeraj.gandotra@samhsa.hhs.gov |